Cymabay Therapeutics, Inc. - Revizia istoricului

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-11-24T17:00:48Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 24 noiembrie 2024 20:00
Linia 2:		Linia 2:

	==Descriere companie==		==Descriere companie==
	CymaBay Therapeutics, Inc. (www.cymabay.com) is a clinical-stage biopharmaceutical company. The company is focused on developing and providing access to therapies for patients with liver and other chronic diseases. Its pipeline includes three clinical stage product candidates, such as seladelpar, MBX-2982 and CB-0406. It also has [[one]] preclinical stage product candidate, CB-001. The Company's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. Its MBX-2982 targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Its CB-001 targets G protein-coupled receptor 120 (GPR120), a receptor for omega-3 fatty acids, such as docosahexaenoic acid (DHA).		CymaBay Therapeutics, Inc. (www.cymabay.com) is a clinical-stage biopharmaceutical company. The company is focused on developing and providing access to therapies for patients with liver and other chronic diseases. Its pipeline includes three clinical stage product candidates, such as seladelpar, MBX-2982 and CB-0406. It also has [[one]] preclinical stage product candidate, CB-001. The Company's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor [[DELTA\|delta]] (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. Its MBX-2982 targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Its CB-001 targets G protein-coupled receptor 120 (GPR120), a receptor for omega-3 fatty acids, such as docosahexaenoic acid (DHA).

	==Grafic actiuni companie==		==Grafic actiuni companie==

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-09-29T19:55:09Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 29 septembrie 2024 22:55
Linia 2:		Linia 2:

	==Descriere companie==		==Descriere companie==
	CymaBay Therapeutics, Inc. (www.cymabay.com) is a clinical-stage biopharmaceutical company. The company is focused on developing and providing access to therapies for patients with liver and other chronic diseases. Its pipeline includes three clinical stage product candidates, such as seladelpar, MBX-2982 and CB-0406. It also has one preclinical stage product candidate, CB-001. The Company's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. Its MBX-2982 targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Its CB-001 targets G protein-coupled receptor 120 (GPR120), a receptor for omega-3 fatty acids, such as docosahexaenoic acid (DHA).		CymaBay Therapeutics, Inc. (www.cymabay.com) is a clinical-stage biopharmaceutical company. The company is focused on developing and providing access to therapies for patients with liver and other chronic diseases. Its pipeline includes three clinical stage product candidates, such as seladelpar, MBX-2982 and CB-0406. It also has [[one]] preclinical stage product candidate, CB-001. The Company's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. Its MBX-2982 targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Its CB-001 targets G protein-coupled receptor 120 (GPR120), a receptor for omega-3 fatty acids, such as docosahexaenoic acid (DHA).

	==Grafic actiuni companie==		==Grafic actiuni companie==

Admin: Pagină nouă: Pagina dedicata companiei Cymabay Therapeutics, Inc. listata cu simbolul US.CBAY ==Descriere companie== CymaBay Therapeutics, Inc. (www.cymabay.com) is a clinical-stage biopharmaceutical company. The company is focused on developing and providing access to therapies for patients with liver and other chronic diseases. Its pipeline includes three clinical stage product candidates, such as seladelpar, MBX-2982 and CB-0406. It also has one preclinical stage product candidate, CB...

2024-09-18T13:45:19Z

Pagină nouă: Pagina dedicata companiei Cymabay Therapeutics, Inc. listata cu simbolul US.CBAY ==Descriere companie== CymaBay Therapeutics, Inc. (www.cymabay.com) is a clinical-stage biopharmaceutical company. The company is focused on developing and providing access to therapies for patients with liver and other chronic diseases. Its pipeline includes three clinical stage product candidates, such as seladelpar, MBX-2982 and CB-0406. It also has one preclinical stage product candidate, CB...

Pagină nouă

Pagina dedicata companiei Cymabay Therapeutics, Inc. listata cu simbolul US.CBAY

==Descriere companie==
CymaBay Therapeutics, Inc. (www.cymabay.com) is a clinical-stage biopharmaceutical company. The company is focused on developing and providing access to therapies for patients with liver and other chronic diseases. Its pipeline includes three clinical stage product candidates, such as seladelpar, MBX-2982 and CB-0406. It also has one preclinical stage product candidate, CB-001. The Company's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. Its MBX-2982 targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Its CB-001 targets G protein-coupled receptor 120 (GPR120), a receptor for omega-3 fatty acids, such as docosahexaenoic acid (DHA).

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.CBAY" />

==Ultimele stiri despre Cymabay Therapeutics, Inc. (US.CBAY)==
<dynamicpagelist>
category=US.CBAY
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.CBAY]][[Categorie:Stiri despre companii]]